Meta AnalysisID 6378
麝香保心丸治疗冠状动脉慢血流的Meta分析与试验序贯分析
CRD42022329469
To systematically evaluate the efficacy and safety of Shexiang Baoxin Pill in the treatment of coronary slow flow .
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6378
- Evidence Id
- 14936
- Core Evidence Id
- 14936
- Source Meta Analysis Id
- 6361
- Herb2 Meta Analysis Id
- HBMA006361
- Crd Id
- CRD42022329469
- Title
- Meta-analysis and trial sequential analysis of Shexiang Baoxin Pill for coronary slow flow
- Review Question
- To systematically evaluate the efficacy and safety of Shexiang Baoxin Pill in the treatment of coronary slow flow .
- Study Type Included
- Only RCT
- Condition Being Studied
- Coronary slow flow is a cardiovascular disease with angina pectoris as the main symptom, except for cardiomyopathy, connective tissue disease, structural heart disease, coronary artery dilation and spasm, and no significant stenosis on coronary angiography, but with delayed perfusion in the distal coronary arteries. As a chronic disease of non-instrumental lesions, CSF patients are easily seen due to recurrent chest pain attacks, which seriously affect the normal life and work and reduce their quality of life. But the pathogenesis of CSF in modern medicine is not yet fully clarified, and there is no effective unified treatment plan for the time being. So it is important to explore the methods of traditional Chinese medicine with exact effect and easy to use.
- Participant
- Patients who meet the diagnostic criteria for CSF, regardless of disease duration, gender, age, and region. The diagnostic criteria were referred to the corrected TIMI frame count (CTFC) method of Gibson et al., and CSF was diagnosed when CTFC was > 27 frames after coronary angiography
- Animal
- Human Disease Modelled
- Intervention
- The experimental group was added with Shexiang Baoxin Pills (produced by Shanghai Hutchison Pharmaceuticals Co., Ltd.) for adjuvant therapy.
- Comparator Control
- Control group was treated with antiplatelet drugs, lipid-lowering drugs, vasodilators of nitrate and other conventional western medicine
- Main Outcome
- 1) Efficacy on angina pectoris (assessment criteria refer to Guidelines for Clinical Research of New Drugs of Traditional Chinese Medicine), overall response rate = (markedly effective + effective)/total number of cases × 100%;
- Outcome Measure
- Additional Outcome
- 2) CTFC; 3) Positive rate of treadmill exercise test (determination criteria refer to Guidelines for Clinical Research of New Drugs of Traditional Chinese Medicine); 4) Endothelin-1 (ET-1) level; 5) nitric oxide (NO) level; 6) High-sensitivity C-reactive protein (hs-CRP) level; 7) Adverse reactions.
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Drugs, Chinese Herbal; Humans; shexiang baoxin
- Contact
- Hongxin Guo [email protected]
- Organisational Affiliation
- Henan University of Chinese Medicine
- Funding Source
- The study was supported by the Key Special Project of the National Key R & D Program (2019YFC1710003, 2019YFC1710000), the Key Project of the National Natural Science Foundation of China (82030120) and Henan Province Traditional Chinese Medicine Scientific Research Special Project (2018JDZX009).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-04-30
- Registration Date
- 2022-05-11
- Anticipated Start Date
- 2022-04-30
- Anticipated Completion Date
- 2022-05-31
- Title Cn
- 麝香保心丸治疗冠状动脉慢血流的Meta分析与试验序贯分析
- Title En
- Meta-analysis and trial sequential analysis of Shexiang Baoxin Pill for coronary slow flow
- Bilingual Status
- complete